<code id='DB1586BAB5'></code><style id='DB1586BAB5'></style>
    • <acronym id='DB1586BAB5'></acronym>
      <center id='DB1586BAB5'><center id='DB1586BAB5'><tfoot id='DB1586BAB5'></tfoot></center><abbr id='DB1586BAB5'><dir id='DB1586BAB5'><tfoot id='DB1586BAB5'></tfoot><noframes id='DB1586BAB5'>

    • <optgroup id='DB1586BAB5'><strike id='DB1586BAB5'><sup id='DB1586BAB5'></sup></strike><code id='DB1586BAB5'></code></optgroup>
        1. <b id='DB1586BAB5'><label id='DB1586BAB5'><select id='DB1586BAB5'><dt id='DB1586BAB5'><span id='DB1586BAB5'></span></dt></select></label></b><u id='DB1586BAB5'></u>
          <i id='DB1586BAB5'><strike id='DB1586BAB5'><tt id='DB1586BAB5'><pre id='DB1586BAB5'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          Wikipedia

          author:focus    - browse:254
          Scorecard
          Ryan Pierse/Getty Images

          Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

          In December, Vertex Pharmaceuticalsannounced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.

          advertisement

          The next big test of Alnylam Pharmaceuticals’pipeline of RNA-interference medicines looms with the outcome of a Phase 3 study called HELIOS-B that is investigating vutrisiran as a treatment for ATTR-CM, a progressive disease that leads to heart failure.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time